Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer
January 04, 2017 08:00 ET
|
Heat Biologics
Industry veteran, Dr. Hutchins, to advance Heat’s platform technologies and pursue immunotherapy combinationsFormer CSO Taylor Schreiber, M.D., Ph.D., to chair Heat’s Scientific Advisory Board and...
Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results
December 06, 2016 08:20 ET
|
Heat Biologics
Reports Positive Data on Primary Endpoint with Positive Safety Data Overall Survival Compares Favorably with Single-Agent Nivolumab Management to host a call on Thursday, December 8th, at 8:30 a.m....
Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results at the Society of Urological Oncology Annual Meeting
November 30, 2016 17:27 ET
|
Heat Biologics
DURHAM, N.C., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the development of gp96-based immunotherapies that are designed to activate a patient’s immune system...
Heat Biologics to Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results at the International Society for the Study of Lung Cancer Annual Meeting
November 17, 2016 07:00 ET
|
Heat Biologics
DURHAM, N.C., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the development of gp96-based immunotherapies that are designed to activate a patient’s immune system...
Heat Biologics to Present Topline HS-410 Phase II Bladder Cancer Results at the Society of Urological Oncology Annual Meeting
November 16, 2016 07:00 ET
|
Heat Biologics
DURHAM, N.C., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the development of gp96-based immunotherapies that are designed activate a patient’s immune system...
Heat Biologics Presents ComPACT Preclinical Data at the Society for Immunotherapy of Cancer Annual Meeting
November 14, 2016 07:00 ET
|
Heat Biologics
Enhanced Tumor Rejection in Colorectal Cancer Mouse Model Combined Synergistically with PD1 and PD-L1 Checkpoint Inhibitors DURHAM, N.C., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc....
Heat Biologics Provides Corporate Update and Reports Third Quarter 2016 Financial Results
November 10, 2016 16:46 ET
|
Heat Biologics
DURHAM, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against...
Heat Biologics to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 07, 2016 07:00 ET
|
Heat Biologics
DURHAM, N.C., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq:HTBX), a leader in the development of gp96-based immunotherapies that activate a patient’s immune system to fight...
Heat Biologics and University of Miami Announce Zika Vaccine Collaboration
October 25, 2016 07:00 ET
|
Heat Biologics
New Infectious Disease Subsidiary to Apply Heat’s Proprietary Platform Technology to Zika Virus and Other Infectious Diseases Program to Focus on Protecting the Fetus from Zika...
Heat Biologics to Present at Two Upcoming Investor Conferences and Panel Discussion
October 17, 2016 07:30 ET
|
Heat Biologics
DURHAM, N.C., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against...